Furthermore, alemtuzumab, an anti‐CD52 antibody 28, or elotuzumab, a humanized monoclonal antibody against the surface antigen SLAMF7 29, may offer new treatment options in systemic AL amyloidosis for positive patients. Here, SLAMF7 is linked to primary systemic amyloidosis.